BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

As far we know, this is the first published tined lead implantation which was guided based on the surgical navigation and intraoperative O-arm images. The method is slightly more invasive than the ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Contemporary techniques for sacral nerve stimulation (SNS) are considered to involve easy, straightforward procedures and minimal invasiveness. As a result, SNS is now routinely incorporated into ...

Sacral nerve stimulation (SNS) is FDA-approved for chronic urge incontinence, urinary urgency and frequency, and nonobstructive urinary retention. In children, retrospective studies of SNS have ...

“Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-analysis” highlights the efficacy and safety of iTNM for treating UUI and ...

Axonics Modulation Technologies ( (AXNX) ) has released its Q3 earnings. Here is a breakdown of the information Axonics Modulation Technologies ...